Phentermine is a prescription medication classified as a sympathomimetic amine. It is FDA-approved for short-term adjunct to a reduced-calorie diet and increased physical activity.
It works by stimulating the release of norepinephrine in the brain which reduces hunger and helps control caloric intake. Phentermine is FDA-approved for short-term use (12 weeks) as part of a comprehensive weight-loss plan that includes a reduced-calorie diet, exercise, and behavioral modifications. It is intended for patients with obesity (BMI ≥30 kg/m²) or overweight patients (BMI ≥27 kg/m²) who also have weight-related risk factors (such as hypertension, type 2 diabetes, or hyperlipidemia).
Phentermine is a Schedule IV controlled substance. It is available by prescription only and must be used under the supervision of a licensed healthcare provider. The information provided here is for educational purposes only and should not replace professional medical advice. Your healthcare provider will determine whether phentermine is appropriate for you.
As determined by a licensed medical provider, phentermine can may be combined with certain other medications for additional benefits tailored to individual patient needs. These combinations target multiple pathways for weight management, addressing issues like cravings, emotional eating, and metabolic health.
Phentermine HCl/topiramate is an FDA approved prescription medication available under the brand name Qsymia or as a generic. It combines two active ingredients medications with complementary mechanisms of action to support weight loss. Phentermine HCl works by suppressing appetite through the release of norepinephrine, which triggers the fight-or-flight response and reduces hunger. Topiramate, originally developed for epilepsy and migraines, enhances feelings of fullness, reduces appetite, and may alter taste perception to minimize cravings. Phentermine HCL/topiramate is classified as a schedule IV controlled substance. It is available by prescription only and must be used under the supervision of a licensed healthcare provider.
WEIGHT LOSS: Studies show an average reduction of up to 10% of body weight with consistent use.
DUAL MECHANISMS: Combines appetite suppression with reduced cravings and overeating behaviors.
TREATMENT DURATION: May be utilized for long-term, chronic weight management.
IMPROVES OBESITY-RELATED COMORBIDITIES: Supports better control of weight-related conditions like hypertension, diabetes, and dyslipidemia.
Pregnancy Warning: Contraindicated in pregnancy due to risk of birth defects (e.g., cleft lip/palate). Recommended that women of child bearing age should take a pregnancy test prior to initiating therapy and monthly pregnancy tests performed throughout therapy. Two acceptable forms of birth control are highly recommended during phentermine HCl/topiramate therapy to prevent pregnancy.
Addiction Risk: Potential for dependency as a stimulant.
CNS Effects: May cause insomnia, agitation, and restlessness. Cognitive issues (e.g., memory problems), mood changes, and sleep disturbances.
Cardiovascular Risk: Increases heart rate and blood pressure; caution in patients with cardiovascular disease.
Nausea and GI Effects: Same as phentermine HCl, with added risk of topiramate’s impact on metabolic acidosis.
Mental Health Warning: May worsen anxiety or agitation. Mood disturbances or depression possible with topiramate.
Contraindications: Avoid in patients with uncontrolled hypertension, hyperthyroidism, or history of drug abuse.
